2024-518143-38-00招募中3 期
PRODIGE 61- FFCD 1702 - FUNGEMAX Randomized phase II study comparing 5FU/LV+Nal-IRI, gemcitabine+Nab-paclitaxel or a sequential regimen of 2 months 5FU/LV+Nal-IRI followed by two months of gemcitabine+Nab-paclitaxel, in metastatic pancreatic cancer
Fondation Franc.Cancerologie Digestive1 个研究点 分布在 1 个国家目标入组 288 人开始时间: 2024年10月25日最近更新:
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 288
- 试验地点
- 1
- 主要终点
- The primary endpoint is the rate of patients alive without progression at 6 months after inclusion
研究概览
简要总结
- Compare the progression free survival at 6 months in experimental arms (arm A: Nal-Iri plus 5FU/LV and Nab-Paclitaxel plus Gemcitabine alternatively, arm B: Nal-Iri plus 5FU/LV) VS the reference arm (arm C: Nab-Paclitaxel plus Gemcitabine) according to the RECIST 1.1 criteria
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •Histopathologically or cytologically proven pancreatic adenocarcinoma (on primitive or metastatic lesion)
- •Normal ECG or ECG without any clinically significant findings
- •Patient able to understand and sign an informed consent
- •Females of child-bearing potential are required to test negative for pregnancy at the time of enrollment based on a urine or serum pregnancy test.
- •Both male and female patients of reproductive potential were required to agree to use a reliable method of birth control, during the study and for 7 months following the last dose of study drug.
- •Patient affiliated to social security - Regular follow-up possible
- •Metastatic disease at a distance
- •At least one measurable lesion according RECIST v1.1 criteria
- •18 ≤ age ≤ 75 years - Life expectancy >12 weeks - Performance status WHO < 2
- •No prior chemotherapy: adjuvant chemotherapy by gemcitabine +/- capecitabine is allowed if ended at least 12 months before the inclusion and adjuvant or neo-adjuvant FOLRIFINOX chemotherapy is allowed if ended at least 12 months prior the inclusion
- •Pain well controlled before the inclusion of the patient
- •ANC ≥ 1,500 cells/μL (without the use of hematopoietic growth factors); platelet count ≥ 100,000 cells/μL, hemoglobin ≥ 9 g/dL (blood transfusions is permitted for patients with hemoglobin levels below 9 g/dL)
- •Adequate hepatic function as evidenced by: Serum total bilirubin within normal range for the institution (Serum bilirubin ≤ 1,5 UNL) Biliary drainage allowed for biliary obstruction.
- •Albumin levels ≥ 3.0 g/dL - Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN (≤ 5 x ULN acceptable if liver metastases were present) - Normal renal function test (creatinine clearance ≥ 50 ml/min)
排除标准
- •Uncontrolled brain or meningeal metastasis, or bone metastasis (no need of systematic CT scan)
- •NYHA Class III or IV congestive heart failure, ventricular arrhythmias or uncontrolled blood pressure.
- •Known hypersensitivity to any of the drugs /constituents or non-lipososomal irinotecan
- •Any other medical or social condition deemed by the investigator to be likely to interfere with a patient’s ability to sign informed consent, cooperate and participate in the study, or interferes with the interpretation of the results
- •Use of CYP3A4/UGT1A inducers/inhibitors
- •Use of strong CYP2C8 inhibitors or inducers, or presence of any other contraindications for nab-paclitaxel or gemcitabine
- •ILD presence
- •Partial or complete DPD deficiency (Uracilemia ≥ 16 ng/ml)
- •Pregnant or breast feeding
- •Prior radiation therapy (except if there is at least one measurable target outside irradiation area)
- •Clinically significant gastrointestinal disorder including hepatic disorders, bleeding, inflammation, occlusion, or diarrhea > Grade 1
- •History of chronic inflammatory bowel disease
- •Other types of pancreatic tumours, in particular endocrine or acinar cell tumours
- •Ampulloma - Gilbert's syndrome
- •Presence of neuropathy > grade 1 according to NCI-CTC
- •History of any second malignancy in the last 5 years; subjects with prior history of in-situ cancer or basal or squamous cell skin cancer are eligible. Subjects with other malignancies are eligible if they had been continuously disease free for at least 5 years.
- •Severe arterial thromboembolic events (myocardial infarction, unstable angina pectoris, stroke) less than 6 months before inclusion.
结局指标
主要结局
The primary endpoint is the rate of patients alive without progression at 6 months after inclusion
The primary endpoint is the rate of patients alive without progression at 6 months after inclusion
次要结局
- Best Objective Response (BOR): BOR is defined as complete or partial response rate according to scans and RECIST v1.1 criteria over the entire treatment period.
- Progression free survival (PFS): PFS is defined as the time between the date of randomization and the date of the first radiological and/or clinical progression or the date of death (for whatever reason).
- Overall survival (OS): OS is defined as the time between the date of randomization and the date of death (whatever the cause).
- Depth of response: This is defined as the relative difference between the sum of the largest diameters of target lesions in the NADIR (in the absence of new lesions or progression of non-target lesions) and the sum of the largest diameters of the target lesions at inclusion.
- Early tumor shrinkage: This is defined as the relative difference between the sum of the largest diameters of target lesions at 8 weeks and this sum at inclusion. Early decrease corresponds to a relative difference of > 20% in RECIST v1.1.
- Time to treatment failure is defined as the time between the date of randomization and the date of discontinuation of all protocol treatments (regardless of cause) or date last news for patients alive under treatment.
- Safety: Toxicities are evaluated according to NCI-CTC v4.0.
- Quality of life (EORTC QLQ-C30): Quality of life will be assessed according to the questionnaire of EORTC QLQ-C30
- Evolution of tumoral markers: The evolution of the markers will be analysed by a graphical representation at each time points of the percentage change from baseline.
研究者
JULIEN TAIEB
Scientific
Fondation Franc.Cancerologie Digestive
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
Combination of Nal-IRI and 5-Fluorouracil compared to 5-Fluorouracil alone in patients with cholangio- and gallbladder cancer previously treated with gemcitabine-based therapiesadvanced, unresectable and metastatic cholangio- and gallbladder carcinomaMedDRA version: 20.0Level: PTClassification code 10008593Term: CholangiocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10077846Term: Cholangiocarcinoma metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: HLTClassification code 10017634Term: Gallbladder neoplasms malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10051667Term: Metastases to gallbladderSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10017614Term: Gallbladder cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-003709-33-DEAIO-Studien-gGmbH100
招募中
2 期
A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC)Metastatic Pancreatic Ductal AdenocarcinomaNCT05472259Belgian Group of Digestive Oncology134
进行中（未招募）
不适用
A Randomised Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin versus 5FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Proapectively the Prognostic Value of Molecular MarkersEUCTR2007-001195-36-IEAll Ireland Cooperative Oncology Research Group (ICORG)3,610
已完成
不适用
Phase II randomized trial comparing 5-fluorouracil in continuous infusion and cisplatin (FP) versus leucovorin, bolus 5-fluorouracil and cisplatin (FLP) in metastatic gastric, pancreatic and oesophageal cancerMetastatic gastric, pancreatic and oesophageal cancerOesophagealCancerISRCTN05842222French Federation of Digestive Cancers (Fédération Francophone de la Cancérologie Digestive [FFCD]) (France)232
进行中（未招募）
1 期
Evaluation of the efficacy of a combinaison treatment based upon immunotherapy + chemotherapy to treat patient with a stomach cancerAdvanced gastric or gastro-oesophageal junction adenocarcinomaMedDRA version: 20.0 Level: LLT Classification code 10042080 Term: Stomach cancer System Organ Class: 100000004864MedDRA version: 20.0 Level: LLT Classification code 10026476 Term: Malignant neoplasm of stomach System Organ Class: 100000004864EUCTR2018-002014-13-FRFédération Francophone de Cancérologie Digestive94